Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2008. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction rather than general financial performance.
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The only change noted is an increase in the shareholding of Dr. R G Greig.
Management Commentary and Risks
The filing details a transaction notified under Disclosure and Transparency Rule 3.1.4R(1)(a). Dr. R G Greig's interest in Ordinary share ADRs increased following the re-investment of the dividend paid to shareholders on April 10, 2008. The transaction occurred at a price of $43.87 per ADR. No other risks, contingencies, or unusual items are discussed.
Investor Verification Points
- Verify the total number of ADRs held by Dr. R G Greig following this transaction.
- Confirm the dividend amount reinvested on April 10, 2008.
- Check for any other director transactions reported in subsequent filings.